1. Home
  2. TNGX vs RYET Comparison

TNGX vs RYET Comparison

Compare TNGX & RYET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • RYET
  • Stock Information
  • Founded
  • TNGX 2014
  • RYET 2012
  • Country
  • TNGX United States
  • RYET China
  • Employees
  • TNGX N/A
  • RYET N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • RYET
  • Sector
  • TNGX Health Care
  • RYET
  • Exchange
  • TNGX Nasdaq
  • RYET NYSE
  • Market Cap
  • TNGX 317.4M
  • RYET 271.4M
  • IPO Year
  • TNGX N/A
  • RYET 2025
  • Fundamental
  • Price
  • TNGX $1.14
  • RYET $9.45
  • Analyst Decision
  • TNGX Strong Buy
  • RYET
  • Analyst Count
  • TNGX 7
  • RYET 0
  • Target Price
  • TNGX $12.33
  • RYET N/A
  • AVG Volume (30 Days)
  • TNGX 532.3K
  • RYET 559.9K
  • Earning Date
  • TNGX 05-12-2025
  • RYET 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • RYET N/A
  • EPS Growth
  • TNGX N/A
  • RYET N/A
  • EPS
  • TNGX N/A
  • RYET N/A
  • Revenue
  • TNGX $42,069,000.00
  • RYET $6,989,985.00
  • Revenue This Year
  • TNGX N/A
  • RYET N/A
  • Revenue Next Year
  • TNGX N/A
  • RYET N/A
  • P/E Ratio
  • TNGX N/A
  • RYET N/A
  • Revenue Growth
  • TNGX 15.17
  • RYET N/A
  • 52 Week Low
  • TNGX $1.11
  • RYET $4.00
  • 52 Week High
  • TNGX $12.02
  • RYET $8.92
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 36.06
  • RYET N/A
  • Support Level
  • TNGX $1.03
  • RYET N/A
  • Resistance Level
  • TNGX $1.56
  • RYET N/A
  • Average True Range (ATR)
  • TNGX 0.15
  • RYET 0.00
  • MACD
  • TNGX -0.01
  • RYET 0.00
  • Stochastic Oscillator
  • TNGX 17.74
  • RYET 0.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About RYET RUANYUN EDAI TECHNOLOGY INC

Ruanyun Edai Technology Inc is primarily engaged in providing online academic exercise question banks with A.I. capabilities, online classes and homework, and on-demand lectures and evaluations that cover all K-12 subject fields and grade levels.

Share on Social Networks: